This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Dermatologic Disorders  • Psoriasis  • Dermatologic Procedures  • Phototherapy  • Alert me on articles by topic  Social Bookmarking   What's this?

David M. Pariser, MD; Jerry Bagel, MD; Joel M. Gelfand, MD, MSCE; Neil J. Korman, MD, PhD; Christopher T. Ritchlin, MD; Bruce E. Strober, MD, PhD; Abby S. Van Voorhees, MD; Melodie Young, MSN, RN, ANP; Sheila Rittenberg, BA; Mark G. Lebwohl, MD; Elizabeth J. Horn, PhD; for the National Psoriasis Foundation

Arch Dermatol. 2007;143(2):239-242.

Objectives  A task force of the National Psoriasis Foundation Medical Board was convened to evaluate the current severity criteria of mild, moderate, and severe psoriasis and to make recommendations concerning a 2-tiered categorization of severity based on current clinical practice and related to intent to treat.

Participants  This volunteer task force, led by David M. Pariser, MD, included Jerry Bagel, MD, Joel M. Gelfand, MD, MSCE, Neil J. Korman, MD, PhD, Christopher T. Ritchlin, MD, Bruce E. Strober, MD, PhD, Abby S. Van Voorhees, MD, and Melodie Young, MSN, RN, ANP. Meetings were held by teleconference and were coordinated and funded by the National Psoriasis Foundation.

Evidence  This task force reviewed psoriasis severity criteria and other published psoriasis consensus statements. Current standards of care and expert opinion were used to inform the process.

Consensus Process  Based on meetings of the task force and under the guidance of David M. Pariser, MD, a statement was drafted by Elizabeth J. Horn, PhD, presented to the task force, and reviewed and approved by the task force. This statement was then reviewed and approved by Robert E. Kalb, MD, Gerald G. Krueger, MD, and Alan Menter, MD. The National Psoriasis Foundation Medical Board reviewed and endorsed this statement by a majority vote on March 2, 2006, at the medical board meeting.

Conclusions  This clinical consensus statement proposes a 2-tiered system for plaque psoriasis therapy that reflects more accurately than the current system how patients are treated in clinical practice. This statement, focused on plaque psoriasis, is intended to assist medical professionals and insurance payers in understanding these 2 categories of patients with psoriasis and choosing appropriate therapies for these patients.

Author Affiliations: Department of Dermatology, Eastern Virginia Medical School, Norfolk (Dr Pariser); College of Physicians and Surgeons of Columbia University, New York, NY, and Psoriasis Treatment Center of Central New Jersey, East Windsor (Dr Bagel); Department of Dermatology (Drs Gelfand and Van Voorhees) and Center for Clinical Epidemiology and Biostatistics (Dr Gelfand), University of Pennsylvania, Philadelphia; Murdough Family Center for Psoriasis, Case Western Reserve University/University Hospital of Cleveland, Cleveland, Ohio (Dr Korman); Clinical Immunology Research Center, University of Rochester School of Medicine & Dentistry, Rochester, NY (Dr Ritchlin); Ronald O. Perelman Department of Dermatology, New York University (Dr Strober), and Mount Sinai School of Medicine (Dr Lebwohl), New York; and National Psoriasis Foundation, Portland, Ore (Ms Rittenberg and Dr Horn). Ms Young works in a private practice in Dallas, Tex.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED ARTICLES

Psoriasis and Pustular Dermatitis Triggered by TNF- Inhibitors in Patients With Rheumatologic Conditions
Gillian C. de Gannes, Mehran Ghoreishi, Janet Pope, Anthony Russell, David Bell, Stewart Adams, Kamran Shojania, Magdalena Martinka, and Jan P. Dutz
Arch Dermatol. 2007;143(2):223-231.
ABSTRACT | FULL TEXT  

The Yin and Yang of TNF- Inhibition
David F. Fiorentino
Arch Dermatol. 2007;143(2):233-236.
EXTRACT | FULL TEXT  

Onset of Psoriasis During Treatment With TNF- Antagonists: A Report of 3 Cases
Ravi Ubriani and Abby S. Van Voorhees
Arch Dermatol. 2007;143(2):270-272.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

The Role of Online Support Communities: Benefits of Expanded Social Networks to Patients With Psoriasis
Idriss et al.
Arch Dermatol 2009;145:46-51.
ABSTRACT | FULL TEXT  

Long-term Treatment for Severe Psoriasis: We're Halfway There, With a Long Way to Go
Gelfand
Arch Dermatol 2007;143:1191-1193.
FULL TEXT  

What Is Severe Psoriasis?
Journal Watch Dermatology 2007;2007:1-1.
FULL TEXT